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Abstract
The snoMEN (snoRNAModulator of gene ExpressioN) vector technology was developed
from a human box C/D snoRNA, HBII-180C, which contains an internal sequence that can
be manipulated to make it complementary to RNA targets, allowing knock-down of targeted
genes. Here we have screened additional human nucleolar snoRNAs and assessed their
application for gene specific knock-downs to improve the efficiency of snoMEN vectors. We
identify and characterise a new snoMEN vector, termed 47snoMEN, that is derived from
box C/D snoRNA U47, demonstrating its use for knock-down of both endogenous cellular
proteins and G/YFP-fusion proteins. Using multiplex 47snoMEM vectors that co-express
multiple 47snoMEN in a single transcript, each of which can target different sites in the
same mRNA, we document >3-fold increase in knock-down efficiency when compared with
the original HBII-180C based snoMEN. The multiplex 47snoMEM vector allowed the con-
struction of human protein replacement cell lines with improved efficiency, including the
establishment of novel GFP–HIF-1α replacement cells. Quantitative mass spectrometry
analysis confirmed the enhanced efficiency and specificity of protein replacement using the
47snoMEN-PR vectors. The 47snoMEN vectors expand the potential applications for sno-
MEN technology in gene expression studies, target validation and gene therapy.
Introduction
Small nucleolar RNAs (snoRNAs) are a class of conserved RNAs first identified as guides for
site specific post-transcriptional modifications in ribosomal RNA (rRNA) [1–4]. The majority
of snoRNAs are processed from introns and carry out their function in complex with specific
protein interactors, forming ribonucleoprotein complexes, which are referred to as small nucle-
olar ribonucleoproteins (snoRNPs). Two main groups of snoRNAs have been described.
Box C/D snoRNAs form functional complexes in vivo with snoRNA associated proteins, such
as NOP56, NOP58, 15.5K and the highly conserved protein fibrillarin, which is responsible for
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rRNA 20-O-ribose methylation. Human box C/D snoRNA molecules are typically 70–120
nucleotides in length and are mainly encoded in the introns of protein-coding genes. They can
be excised from introns through at least two distinct pathways, then further processed and
assembled with conserved proteins, including the 2’-O-methyl transferase fibrillarin [4, 5].
Box C/D snoRNAs are characterized by the presence of two, short, conserved motifs, i.e., the C
box (UGAUGA) and the D box (CUGA), found near the 5’ and 3’ ends of the molecule, respec-
tively (for example, see Fig 1A). The guide sequence with complementarity to the target is
located immediately 5’ to the stem II & box D region.
The box H/ACA snoRNAs, which bind the four conserved core proteins DKC1 (dyskerin),
GAR1, NHP2 and NOP10, catalyse pseudouridylation at specific target sites on rRNA [2, 3].
Human box H/ACA snoRNAs consist of two hairpins and two short single-stranded regions,
which contain the H box (ANANNA) and the ACA box. The latter is always located 3 nucleo-
tides 5' of the 3' end of the snoRNA (for example, see Fig 1A). The hairpins contain bulges, or
recognition loops, that form complex pseudo-knots with the target RNA, where the target uri-
dine is the first unpaired base. The position of the substrate uridine always resides 14–16 nucle-
otides upstream of either the H box, or of the ACA box. Some box H/ACA snoRNAs can guide
the modification of two uridines, sometimes in two different rRNAs.
Many box C/D and box H/ACA snoRNAs and a subset of their target sites in rRNA are con-
served from yeast through to mammalian cells. However, numerous orphan box C/D and
box H/ACA snoRNAs have also been identified that do not encode a region of complementar-
ity to rRNA and whose functions remain unknown [4, 6].
We have previously characterised human nucleolar snoRNAs that co-purify with nucleoli
isolated from HeLa cells. This led us to identify a novel group of related fibrillarin-associated
box C/D snoRNAs that allowed the development of a new vector-based technology for the tar-
geted knock-down of expression of one or more proteins in mammalian cells, termed snoMEN
(snoRNAModulator of Gene Expression) [7, 8]. The snoMEN vectors were developed from
modified versions of the human box C/D small nucleolar RNA (snoRNA) HBII-180C (also
known as SNORD88C). To knock-down the expression levels of specific gene targets, a short
internal snoRNA region, termed the M box, is manipulated to make it complementary to the
selected target RNA sequence. Briefly, specific features of the snoMEN vector technology, in
comparison with other knock-down systems, include a) snoMEN target nuclear RNAs, e.g.
pre-mRNAs and non-coding RNAs [8, 9], b) snoMEN RNAs are transcribed from RNA poly-
merase II promoters, rather than the RNA polymerase III promoters used in shRNA plasmids,
c) multiple snoMEN RNAs can be incorporated within a single transcript and expressed under
the regulation of a single promoter [7].
The snoMEN vectors can be used for a wide variety of gene-regulation studies, including
knock-down and/or knock-in analysis. For example, snoMEN vectors have been shown to
facilitate the establishment of human protein replacement stable cell lines, targeting genes
encoding proteins that are problematic to target using shRNA vectors [9]. Knock-down strate-
gies will in practice result in incomplete removal of the targeted protein, with only either chro-
mosomal deletion, or mutation, of the cognate gene guaranteeing complete removal of the
protein. Nonetheless, analysis of snoMEN protein replacement stable cell lines showed that
even although the protein replacement was partial, it was still sufficient to allow the establish-
ment of stable cell lines for proteins that are toxic when exogenous fusion proteins are simply
overexpressed in the presence of unaltered levels of the endogenous factors [9].
In this study, we screen additional human snoRNAs for use as snoMEN vectors and report
the identification of novel snoMEN that can deliver enhanced efficiency of knock down and
protein replacement. We show these enhanced snoMEN vectors allow the establishment of
new human protein replacement stable cell lines, including replacement of the endogenous
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Fig 1. Structures of newly characterised snoMEN vectors. (a) Predicted secondary structure of the candidate snoRNAs used for
snoMEN vectors. The characteristic features of members of the box C/D and box H/ACA snoRNAs are shown. Conserved box C & D and H
& ACAmotifs are indicated by orange and blue boxes, respectively. The positions of rRNA complementary sequences are indicated by a
green bar. The positions of the M box regions that can be altered to modulate target gene expression (snoMEN vector) are indicated by a
cyan bar. (b) The vector structure used for targeted suppression of GFP fusion proteins. The sequence in wild type U47 snoRNA that is
complementary to pre-mRNAs was changed from 5’-AUAUAAUGAUAUCACUGUAAAAC-3’ to 5’-UCACCUUGAUGCCGUUCUUCUGC-3’
(U47 snoMEN). The resulting U47 snoMEN was subcloned into the 5’ region of the vector with mCherry fluorescent protein cDNA. Diagram
shows complementary regions of U47 snoMEN targeting the GFP cDNA sequence (Anti-GFP mRNA). A mutant U47 snoMEN expression
plasmid with the box D core motif mutatated was also constructed, shown as BoxDmut on the sequence. The motif labels are the same as in
(a).
doi:10.1371/journal.pone.0154759.g001
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HIF-1α protein with GFP–HIF-1α, which previously was refractive to knock-in using alterna-
tive technological approaches.
Results
snoRNA candidates of snoMEN knock-down vector
First, to identify novel snoMEN candidates, we investigated how many human snoRNAs dis-
play regions of complementarity to sequences in pre-mRNA, that are at least as long as those
present in HBII-180C [7], using the human genome database [10]. This in silico analysis identi-
fied that 374 of 377 human snoRNAs have a potential M box (messenger RNA complementary
box) sequence (S1 Data). Next, we selected 8 candidate snoRNAs from this list, prioritising
snoRNAs identified in a human nucleolar cDNA library that show high expression levels [7].
The selected snoRNAs analysed were HBII-52, HBII-85, HBII-239, U47, U77, ACA5, ACA16
and hsa-miR-566 precursor. We carried out preliminary experiments to test whether the above
set of 8 snoRNAs will show any knock-down of a targeted GFP reporter protein when their
endogenous M-box sequence is replaced with a sequence complementary to GFP mRNA.
Transient transfection experiments indicated that 4 of these 8 snoRNAs, i.e. U47, U77, ACA16
and hsa-miR-566 precursor, showed some degree of knock-down of GFP fluorescence levels,
relative either to mock transfected control cells, or to cells transiently transfected with control
vectors not targeted to GFP (data not shown). Therefore, we concentrated follow up analysis
on these 4 snoRNAs (Fig 1A and Fig A in S1 File).
The U47/U77 and ACA16 are well-characterised box C/D and box H/ACA snoRNAs,
respectively [11–15]. The hsa-miR-566 precursor was annotated as a precursor of microRNA
566 (miR-566) from deep sequencing studies [16]. However, our nucleolar cDNA library iden-
tified that there are miR-566 precursor molecules in purified human nucleolar preparations
and we have validated this in multiple clones (data not shown). Analysis of the miR-566 pre-
cursor RNA sequence shows a predicted secondary structure resembling a canonical box H/
ACA snoRNA (Fig 1A). Furthermore, experimentally we find this RNA is enriched in purified
nucleoli (Fig B in S1 File). Therefore, we propose that miR-566 is a snoRNA derived RNA
(sdRNA) and that the miR-566 precursor is actually a box H/ACA snoRNA-like molecule.
To evaluate these 4 snoRNAs in more detail for use as a snoRNA modulator of gene expres-
sion (snoMEN) vector, we next examined their subcellular localization. Each snoRNA was
transiently expressed with its endogenous M box region replaced by a sequence complemen-
tary to G/YFP mRNA and subcloned in a plasmid vector upstream (5’) of mCherry fluorescent
protein cDNA, which provides a transfection marker (Fig 1B and Figs C-E in S1 File). Fluores-
cent in situ hybridisation (FISH) analysis was performed on HeLa cells, using fluorescent
labelled snoMEN-specific probes, following transfection of the HeLa cells with each of these
vector constructs. In each case this showed a consistent nuclear localisation pattern for the
exogenously expressed, modified snoRNA, with prominent accumulation in nucleoli. A similar
nucleolar labelling pattern was also seen upon expression of wild type versions of each
snoRNA, i.e. not complementary to G/YFP mRNA (Fig 2WT).
snoMEN RNAs bind core snoRNP proteins
We next investigated whether the snoMEN RNAs bind specifically to either fibrillarin (FBL), a
core component of box C/D snoRNPs, or to Dyskerin (DKC), a core component of box H/
ACA snoRNPs. HeLa cells expressing either YFP-Fibrillarin, or GFP, as a control, were trans-
fected with either U47snoMEN, U77snoMEN, or the original snoMEN RNA HBII-180C [7]
and nuclei isolated from the transfected HeLa cells. Similar experiments were performed trans-
fecting HeLa cells with ACA16snoMEN and miR-566snoMEN, except GFP-Dyskerin
Development and Analysis of a Novel snoMEN Vector
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Fig 2. Expression and localization of snoMEN snoRNAs. Fluorescence In SituHybridisation shows
nuclear localization and also nucleolar accumulation for wild type snoRNAs, i.e. U47, U77, ACA16, miR566,
and snoMEN, i.e. U47snoMEN, U77snoMEN, ACA16snoMEN, miR566snoMEN (Cy3, Red). U3snoRNA
specific probe was also co-hybridised as nucleolar marker (Fl, Green). DNA is stained by DAPI (Blue). Scale
Bar is 10 μm.
doi:10.1371/journal.pone.0154759.g002
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expressing HeLa cells were used instead of the HeLa YFP-Fibrillarin stable cell line (Fig 3A).
Immunoprecipitations were carried out from the resulting nuclear lysates, using an antibody
specific for the G/YFP fluorescent proteins (see Methods). The RNA was isolated from these
samples and analysed by qRT-PCR (see Methods). As shown in Fig 3B (lanes 4, 8 and 20),
Fig 3. Co-immunoprecipitation of snoMENwith snoRNP core proteins. (a) Live cell images of HeLaGFP, HeLaYFP-Fibrillarin (FBL), and
HeLaGFP-Dyskerin (DKC) stable cell lines that stably express free GFP, YFP-Fibrillarin and GFP-Dyskerin, respectively. (b) Extracts were
prepared from HeLa cell lines stably expressing either YFP-Fibrillarin, or free GFP, for box C/D snoRNAs (U47, U77, HBII-180C) and
either GFP-Dyskerin, or free GFP, for box H/ACA snoRNAs (ACA16 and miR566), after transfection of snoMEN expression vectors, as
indicated at the top (U47snoMEN, U77snoMEN, ACA16snoMEN, miR-566snoMEN, and HBII-180CsnoMEN). Extracts were
immunoprecipitated using a monoclonal anti-GFP antibody conjugated to beads (GFP-TRAP_A), with the specificity confirmed by western
blotting [20, 33]. Quantitative RT-PCRwas used to detect co-precipitated U47 snoMEN, U77 snoMEN, ACA16 snoMEN, miR566 snoMEN
and HBII-180C snoMEN snoRNAs (snoMEN), using U3 (box C/D) and E2 (box H/ACA) snoRNAs as a positive and negative control,
respectively, for fibrillarin/dyskerin-associated RNAs. Equal amounts of material were loaded on the IP and Input lanes.
doi:10.1371/journal.pone.0154759.g003
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U47snoMEN, U77snoMEN and HBII-180C snoMEN co-purify specifically with fibrillarin, as
does the positive control U3 snoRNA. In contrast, the box H/ACA snoRNA E2 is not pulled
down with YFP-fibrillarin (Fig 3B lanes 4, 8 and 20). Similar results were observed for
ACA16snoMEN and miR-566snoMEN, where the snoMEN co-purify specifically with dys-
kerin (Fig 3B lanes 12 and 16), as does the E2 box H/ACA snoRNA. In contrast, the control
U3 box C/D snoRNA is not pulled down with GFP-dyskerin. The combination of these
approaches, i.e., nucleolar cDNA cloning, secondary structure analysis, nucleolar localisation,
fibrillarin and dyskerin binding experiments, demonstrate that all of these 4 modified human
snoRNAs behave similarly to the previously analysed HBII-180C snoMEN [7].
Modulated expression of targeted genes
The ability of each new snoMEN vector to modulate expression of stably expressed GFP was
evaluated in HeLa cells. In each case the M box sequence of snoRNAs U47, U77, ACA16 and
hsa-miR-566 precursor, had been replaced with sequences complementary to the coding
sequence of GFP mRNA (Fig 1B and Figs C-E in S1 File). Plasmid vectors encoding mCherry
linked either to wild type snoRNAs, or linked to snoMEN targeted to GFP mRNA, were tran-
siently transfected in HeLa cell lines that stably express GFP-SMN1 (HeLaGFP-SMN) [17] (Fig 4A
and Fig F in S1 File). Expression of mCherry was used as a marker for detecting transfected cells.
A reduced level of GFP-SMN1 fluorescence was observed specifically in cells co-expressing
mCherry and snoMEN (arrowheads), but not upon transient co-expression of controls corre-
sponding to mCherry and wild type snoRNAs (arrow). Furthermore, a reduction in GFP-SMN1
fluorescence was not observed upon transfection with mutant snoMEN expression plasmids
where the sequence of either the box D, or box ACA core motifs, was mutated (arrows).
Analysis of GFP-SMN1 mRNA levels, as determined using quantitative RT-PCR assays,
yielded similar results (Fig 4B). The newly established snoMEN reduced GFP-SMN1 expres-
sion in the HeLaGFP-SMN stable cell line compared with the GFP-SMN1 mRNA expression lev-
els of the control snoRNA, with varying efficiency (U47snoMEN & U77snoMEN:>50%,
ACA16snoMEN &miR-566snoMEN: ~20%) (Fig 4B Control). Control experiments showed
that neither GFP-SMN1 mRNA levels (Fig 4B), nor protein levels (Fig 5), were reduced by
transfecting the same cells with mutant snoMEN expression plasmids. Compared with previ-
ous data for HBII-180C snoMEN targeted to GFP-SMN1 ([9] also see below), these results
indicate that two of the novel box C/D snoRNAs, i.e. U47 and U77, outperform the knockdown
level of the previous HBII-180C snoMEN RNA. As the U47 snoRNA is shorter than U77 and it
is easier to manipulate its sequence, we focussed on characterising U47 in detail to evaluate its
use as a novel snoMEN vector for targeted gene suppression.
Multiplex U47snoMEN vector transcripts
We next investigated the design of vectors that can deliver multiple U47 snoMEN RNAs from
a single transcript. Thus, a triplet U47snoMEN vector was constructed that encodes mCherry
as a transfection marker and three M box-modified U47 snoRNAs, each targeted to different
positions in the GFP mRNA sequence (Fig 6A). FISH analysis, using specific probes for each
U47snoMEN (Fig 6B CM1-3), showed that all three M box-modified U47 snoRNAs were
expressed following transfection and localised in the nucleus in a similar pattern to wild type
U47 snoRNA (Fig 2). As shown in Fig 7, transient transfection of the triple U47snoMEN vec-
tor (U47snoMEN triplet) showed knock-down of fluorescence in cells expressing GFP-fusion
proteins, as did the HBCsnoMEN triplet positive control, which corresponds to the original
HBII-180C snoMEN targeted the same GFP sequences as the U47snoMEN triplet (Fig 7A
arrowhead). Quantification of both relative mRNA and protein levels tested by qRT-PCR
Development and Analysis of a Novel snoMEN Vector
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Fig 4. Comparison of targeted suppression of GFP fusion protein using snoMEN vectors. (a) The effect of U47
snoMEN (left panel) and U77 snoMEN (right panel) constructs on GFP-SMN1 expression in the HeLaGFP-SMN stable cell
line, which expresses GFP fused at the amino terminus of SMN1. Images show the effect of transfecting either wild type
snoRNAs encoded in mCherry expression plasmid mCherry-N1 (WT, Control), expression plasmid U47/U77 snoMEN
(U47snoMEN at left panel, U77snoMEN at right panel), or expression plasmid of U47/U77 boxDmutant snoMEN
(U47snoMEN box Dmut at left panel, U77snoMEN box Dmut at right panel) in the HeLaGFP-SMN stable cell lines. Upper
panels show GFP and mCherry fluorescence signals of images recorded from fixed cells (GFP and mCherry). Lower
panels showmerged images combining the GFP (green) and mCherry (red) signals. Scale bar is 10 μm. The arrows
indicate transfected cells and arrowheads indicate cells showing reduction of the GFP signal. (b) Detection of RNA levels
Development and Analysis of a Novel snoMEN Vector
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(Fig 7B) and western blot (Fig 7C), respectively, showed that the knock-down efficiency was
increased using the triple U47snoMEN vector, as compared either with vectors expressing a
single U47 snoMEN, or with the vectors expressing triple HBII-180C snoMEN (Fig 7B and
7C).
Enhanced protein replacement using the U47snoMEN vector
Next, we tested the knock-down efficiency when targeting U47 snoMEN to an endogenous
gene, rather than to GFP. For this we designed a protein replacement vector, pGFP-SMN1
U47snoMEN-PR (Fig 8A), expressing M box-modified U47 snoRNAs targeted to endoge-
nous SMN1 pre-mRNA specific sequences, based on the U47snoMEN triplet plasmid (Fig
6A). Plasmid pGFP-SMN1HBCsnoMENv1-PR [7] (Fig 8B), encodes a GFP-SMN1 fusion
protein and three M box modified HBII-180C snoRNAs targeted to the same sequence region
as pGFP-SMN1 U47snoMEN-PR, allowing a direct comparison of relative knock-down effi-
ciencies. To optimise the vector design, we also constructed the plasmid pGFP-SMN1HBC
snoMENv2-PR (Fig 8C). This encodes the same HBII-180C snoMEN triplet as pGFP-SMN1
HBCsnoMENv1-PR, but here with the snoMEN sequences upstream (i.e., 5’) of the GFP-
SMN1 fusion protein, to test whether this arrangement affected the efficiency of protein
expression.
Transient transfection of U47snoMEN-PR, HBCsnoMENv1-PR and HBCsnoMENv2-PR
all showed expression of GFP-SMN1, with similar localisation patterns, closely resembling the
localisation of endogenous SMN1, as confirmed by co-localisation with the Cajal body marker
coilin [17] (Fig 8D arrowhead). Western blot analysis was performed to measure the ratio of
GFP-SMN1/endogenous SMN1 protein replacement for each of the snoMEN vectors (Fig 9A).
Both HBII-180C snoMEN expression plasmids, i.e. HBCsnoMENv1-PR and HBCsno-
MENv2-PR, show a reduction in the levels of endogenous SMN1 and either ~20% (HBCsno-
MENv1-PR), or ~80% (HBCsnoMENv2-PR) knock-in of GFP-SMN1 proteins (Fig 9A and
9B, lanes 2 and 4, graphs HBCsnoMENv1-PR and HBCsnoMENv2-PR white and green bars).
This showed that expression of the ‘knock-in’ protein is increased when it is located in the tran-
script downstream (i.e. 3’) of the three snoMEN RNAs. The U47snoMEN-PR expression plas-
mid, meanwhile, showed more efficient (~70%) reduction of the endogenous SMN1 protein
and a correspondingly higher knock-in level of GFP-SMN1 (Fig 9A and 9B, lane 3, graphs
U47snoMEN-PR white and green bars). Analysis of transfection efficiency indicated that ~95%
of HeLa cells were transfected with each of the respective snoMEN-PR plasmids (Fig 9B orange
bars in graph).
The level of GFP-SMN1 fluorescence was compared between the HeLa cells transfected
with either U47snoMEN-PR, HBCsnoMENv1-PR, or HBCsnoMENv2-PR plasmids, respec-
tively (Fig 9C). This shows higher levels of GFP-SMN1 expression in cells transfected with
either U47snoMEN-PR, or HBCsnoMENv2-PR plasmids, as compared with the HBCsno-
MENv1-PR plasmid (Fig 9C). Overall, these results show that the levels of endogenous SMN1
protein can be suppressed more than three times more efficiently using the M box-modified
for GFP-SMN1 by quantitative RT-PCR (qRT-PCR) following transfection of HeLaGFP-SMN stable cell lines, using either
the wild type snoRNAs with mCherry expression plasmid (control), expression plasmid U47 snoMEN (U47snoMEN),
U47snoMEN box Dmut, U77 snoMEN (U77snoMEN), U77 snoMEN box Dmut, ACA16snoMEN (ACA16snoMEN),
ACA16snoMEN box ACAmut, miR-566 snoMEN (miR566snoMEN) or miR566snoMEN box ACAmut. Equal amounts of
total RNA from HeLaGFP-SMN cells, extracted following snoMEN transfection, were used for qRT-PCR reactions. Graph
shows the GFP-SMN1 expression ratio between control and snoMEN/mutant snoMEN transfection measured from four
independent experiments. P-values are significant according to the Student's t-test; *P<0.05, **P<0.01, ***P<0.001.
GFP specific primers and U3 snoRNA specific primers, as a loading control, were used for amplification.
doi:10.1371/journal.pone.0154759.g004
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Fig 5. Western blot analysis for snoMEN knockdown. Knock-down efficiency of each of the snoMEN
plasmids targeted to GFP (U47snoMEN, U77snoMEN, ACA16snoMEN and miR-566snoMEN at the top of
each panel) was tested by western blotting. Detection of protein levels for GFP-SMN1 following transfection
of HeLaGFP-SMN stable cell lines, using either mCherry and wild type snoRNA expression plasmid (control),
snoMEN expression plasmid (U47snoMEN, U77snoMEN, ACA16snoMEN and miR566snoMEN) and mutant
snoMEN expression plasmid (U47snoMEN box Dmut, U77snoMEN box Dmut, ACA16snoMEN box Dmut
and miR566snoMEN box Dmut). An equivalent amount of HeLaGFP-SMN extract was loaded for each lane and
the proteins separated by SDS PAGE, electroblotted onto membrane and probed both with a monoclonal
anti-GFP antibody and with anti-tubulin as a loading control. Graph shows average ratio of GFP-SMN1 signal
Development and Analysis of a Novel snoMEN Vector
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U47 snoRNAs, (i.e. 47snoMEN), as compared with the previously characterised HBII-180C
snoMEN. The data also show that ~5-fold increase in protein expression efficiency can be
achieved by locating all the snoMEN RNAs upstream of the coding sequence of the ‘knock-in’
protein in the vector transcript.
To test the phenotypic effect of SMN1 knock-down by U47snoMEN, the growth rate of
cells was examined by a proliferation assay (Fig 9D). SMN1 depletion is known to cause apo-
ptosis [17]. Transient transfection of either GFP–C1 (GFP: expressing GFP protein alone), or
pGFP–SMN1U47snoMEN-PR (47snoMEN-PR), did not cause either cytotoxicity, or growth
suppression. However, transient transfection of the SMN1-targeted U47snoMEN expression
plasmid (47snoMEN), resulted in pronounced cytotoxicity that was more efficient than the
degree of cytotoxicity caused by transient transfection with the former version of the snoMEN
vector (HBCsnoMEN) (Fig 9D). These results show that the cytotoxicity caused by SMN1
depletion was rescued by snoMEN protein replacement and further confirm the increased effi-
ciency provided by the new U47snoMEN vector.
Establishment of stable protein replacement cell lines using
47snoMEN-PR vectors
We next established a stable human protein replacement U2OS cell line for expression of the
GFP-SMN1 protein, i.e., U2OSGFP–SMN1-47PR using the pGFP-SMN1 U47snoMEN-PR vector (Fig
10A). Consistent with the improvement in vector design shown by the previous transient transfec-
tion assays, this new stable cell line created using 47snoMEN showed greatly reduced expression of
the endogenous SMN1 protein and a more efficient replacement with GFP-SMN1, as compared
with a similar GFP-SMN1 protein replacement stable cell line established using the previous sno-
MEN protein replacement vector (i.e., U2OSGFP–SMN1-PR) [9] (Fig 10B). Proteomic analysis by
SILAC was carried out to analyse the effect of constitutive expression of the pGFP-SMN1 U47sno-
MEN-PR vector by comparing the steady state proteomes of the new U2OSGFP–SMN1-47PR stable
cell line with the parental U2OS cell line (Fig 10C). This showed that ~96% of the>7,200 proteins
detected byMS were expressed at similar levels (<2 fold difference) in both cell lines.
Given the improved performance of the new U47snoMEN vectors, we next sought to estab-
lish a stable knock-in cell line for GFP–HIF-1α (hypoxia-inducible factor-1 alpha), a protein
for which it has previously proven difficult to establish stable cell lines (Fig 11A). HIF-1α is a
transcription factor that is induced under low oxygen conditions, termed Hypoxia. HIF-1α is
hydroxylated by PHD (prolyl hydroxylase) enzymes under normal oxygen conditions (Nor-
moxia) and is degraded by hydroxylation-dependent proteasomal degradation (Fig 11B) [18].
In hypoxia, PHDs show reduced activity, leading to stabilisation of HIF-1α, which can then
form a heterodimer with HIF-1β, which is constitutively expressed under both Normoxia and
Hypoxia conditions.
Previous attempts at creating GFP–HIF-1α stable cell lines have been unsuccessful, as cells
are unable to retain high levels of this protein and still proliferate. Indeed, HeLa cells stably
transfected with GFP–HIF-1α showed reduced expression of endogenous HIF-1α to accom-
modate similar levels of the exogenous tagged version (Fig 11C). These cells were thus unsuit-
able for imaging due to the low GFP signal (Fig 11D). The lack of a convenient system for
efficient protein replacement has thus presented an obstacle to establishing a FP tagged HIF-
1α stable cell line (Fig 11E).
intensity, normalised using the tubulin signal, which calculated from three independent experiments. P-values
are significant according to the Student's t-test; *P<0.05, **P<0.01, ***P<0.001.
doi:10.1371/journal.pone.0154759.g005
Development and Analysis of a Novel snoMEN Vector
PLOS ONE | DOI:10.1371/journal.pone.0154759 April 29, 2016 11 / 28
Fig 6. Triple U47 snoMEN vector. (a) A triple U47 snoMEN construct, which encodes three U47 snoMEN
targeting different GFP regions (CM1-3), was constructed. (b) Fluorescence In Situ Hybridisation using Cy3
labelled U47 snoMEN specific probes (Cy3) showed nuclear localization and nucleolar accumulation. A U3
snoRNA specific probe was also co-hybridised as a nucleolar marker (Fl, Green). DNA is stained by DAPI. Scale
bar is 10 μm. Arrow shows the nucleolus.
doi:10.1371/journal.pone.0154759.g006
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Fig 7. Gene knock-down using snoMEN triplet vector. (a) This shows the same experiment as in Fig 4A, except that the triple U47 snoMEN
(U47snoMEN triplet) and triple HBII-180C snoMEN (HBCsnoMEN triplet) were transfected. Scale bar is 10 μm. (b) This is the same quantification
analysis as shown in Fig 4B, except that the triple U47 snoMEN (U47snoMEN triplet) and triple HBII-180C snoMEN (HBCsnoMEN triplet) were
transfected. Graph shows the GFP-SMN1 expression ratio between control and triple snoMEN transfections, measured from four independent
experiments. P-values are significant according to the Student's t-test; *P<0.05, **P<0.01, ***P<0.001. GFP specific primers and U3 snoRNA
specific primers, as a loading control, were used for amplification. (c) This is the same quantification analysis as shown in Fig 5, except that the
triple U47 snoMEN (U47snoMEN triplet) and triple HBII-180C snoMEN (HBCsnoMEN triplet) were transfected. Graph shows average ratio of
GFP-SMN1 signal intensity, normalised using the tubulin signal, which was calculated from three independent experiments. P-values are significant
according to the Student's t-test; *P<0.05, **P<0.01, ***P<0.001.
doi:10.1371/journal.pone.0154759.g007
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Fig 8. Protein replacement of endogenous SMN1 protein using advanced snoMEN. (a)-(c) Structures are shown for
targeted endogenous SMN1 protein replacement plasmid, using either U47snoMEN (a: pGFP-SMN1 U47snoMEN-PR), or SMN1
protein replacement plasmid using HBII-180C snoMEN (b: pGFP-SMN1 HBCsnoMENv1-PR, c: pGFP-SMN1 HBCsno
MENv2-PR). These constructs have three snoMEN sequences, as in the triple U47 snoMEN plasmid (Fig 6A), except that here
the M box sequences are complementary to sequences in the endogenous SMN1 pre-mRNA. (d) Localisation analysis of
endogenous SMN1 (HeLa: no transfection) and GFP-SMN1 protein (arrowheads), in HeLa cells transiently transfected with the
U47snoMEN-PR, HBCsnoMENv1-PR and HBCsnoMENv2-PR plasmids, respectively. Images show the localisation patterns of
DNA (DAPI, Blue), endogenous SMN1 (FITC)/GFP-SMN1 proteins (GFP, Green) and endogenous p80 coilin protein (Red),
stained as a Cajal body marker. Scale bar is 10 μm.
doi:10.1371/journal.pone.0154759.g008
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Fig 9. Comparison of protein-replacement efficiency. (a) Expression level of endogenous SMN1 and GFP-SMN1
were measured by western blot analysis. Images show an example of a western blot, with shorter exposure in the upper
panel and longer exposure in the lower panel. An equivalent amount of total cell extract from HeLa cells was loaded for
each lane and the proteins separated by SDS PAGE, electroblotted and probed both with a monoclonal anti-SMN1
antibody and with an anti-tubulin antibody as a loading control. (b) The graph shows average signal intensity and
standard deviation for three independent experiments from HeLa cells transiently transfected with U47snoMEN-PR,
HBCsnoMENv1-PR and HBCsnoMENv2-PR plasmids, as shown in Fig 8D. The SMN1/GFP-SMN1 signal ratio was
normalised to the tubulin signal. Ratios were calculated by comparison with endogenous SMN1 signals in control (No
transfection), untransfected cells. Transfection efficiency was determined by counting the number of GFP positive cells in
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To address this using the new 47snoMEN-PR vector system, we constructed the vector
pmCherry–HIF-1α 47snoMEN-PR, which encodes three 47 snoMEN that target three separate
regions of HIF-1α pre-mRNA cloned upstream of mCherry–HIF-1α cDNA (Fig 11A). This
47snoMEN-PR vector was initially evaluated by transiently transfecting U2OS cells (Fig 12).
Transient transfection of pmCherry–HIF-1α 47snoMEN-PR showed expression of mCherry–
HIF-1α with a similar nuclear localisation pattern to that seen with endogenous HIF-1α (Fig
12A). The expression of mCherry–HIF-1α was also confirmed by Western blot analysis (Fig
12B lanes 5–8). The expression of mCherry–HIF-1α was stabilized by MG132 treatment,
which inhibits proteasome activity (Fig 12B lanes 5 and 6) and was also increased by treatment
with DFX and DMOG (Fig 12B lanes 5, 7 and 8), which are inhibitors of PHD enzymes and
thus mimics for hypoxia. These results suggested that the 47snoMEN-PR vector could poten-
tially allow establishment a HIF-1α protein replacement stable cell line that efficiently express
FP tagged–HIF-1α.
Next, we established two different human protein replacement stable cell lines, U2OSGFP–
HIF-1α-47PR and HeLaGFP–HIF-1α-47PR, using the pGFP–HIF-1α 47snoMEN-PR plasmid vector,
which encodes three 47snoMEN that target three separate regions of endogenous HIF-1α pre-
mRNA and a cDNA encoding GFP–HIF-1α that does not include the sequences targeted by
the snoMEN (Fig 11A). Both of these stable cell lines created using 47snoMEN vectors showed
clear expression of GFP–HIF-1α in the presence of the hypoxia mimicking agent DFX (Fig
13A and 13D). We therefore tested how these cells responded to real hypoxia, by exposing
parental U2OS and U2OSGFP–HIF-1α-47PR cells to 1% oxygen for different times. Analysis of the
resulting cell extracts revealed that, upon hypoxia, HIF-1α was stabilised and HIF-dependent
target genes were induced to similar levels as seen in the parental U2OS cells (Fig 13B). We
also tested the level of knock-down achieved by the HIF-1α-snoMEN vector, which induces a
clear, albeit not complete, reduction in the levels HIF-1α (Fig 13C). In addition, we tested if
these cells were suitable to detect physiological hypoxia, as encountered in 3-D cell culture
models. To this end 3-D cultures of HeLaGFP–HIF-1α-47PR cells were grown and levels of GFP–
HIF-1α were analysed by fluorescence imaging (Fig 13D). Importantly, we were able to detect
GFP–HIF-1α in the core of the 3-D culture of HeLaGFP–HIF-1α-47PR cells, which correlated with
the hypoxic core in the centre of tissue when cells are grown in this type of 3-D culture.
These results demonstrate that the pGFP–HIF-1α 47snoMEN-PR cell lines provide the first
reagents suitable for studying processes leading to HIF-1α stabilisation, particularly under live
cell imaging conditions where previously only transient overexpression experiments have been
possible.
Discussion
In this study we have characterised human snoRNAs that co-purify with nucleoli isolated from
HeLa cells and evaluated their use in mammalian cells for targeted gene knock-down in the
snoMEN vector system. Previously, we have shown that the Box C/D nucleolar snoRNA,
100 randomly selected cells (TF efficiency: orange bar). P-values are significant according to the Student's t-test;
*P<0.05, **P<0.01, ***P<0.001. (c) Graph shows a box plot of GFP-SMN1/DAPI signal ratio comparing transfected
U47snoMEN-PR, HBCsnoMENv1-PR and HBCsnoMENv2-PR plasmids. Signals were calculated from 50 randomly
selected cells. (d) Results of proliferation/cytotoxicity assays comparing control and SMN1 protein replacement cells. A
GFP alone expression vector was transiently transfected into HeLa cells as a negative control. The effects of transient
transfection with vectors expressing either endogenous SMN1 targeted 47snoMEN, HBCsnoMEN without SMN1
expression (47snoMEN and HBCsnoMEN), or pGFPSMN1-U47snoMEN-PR (47snoMEN-PR), were also measured.
Note, both 47snoMEN and HBCsnoMEN showed cytotoxic effects when transiently transfected into HeLa cells, however,
this cytotoxicity was rescued by transfection with the 47snoMEN-PR vector. P-values are significant according to the
Student's t-test (P<0.05).
doi:10.1371/journal.pone.0154759.g009
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Fig 10. Establishment of human protein replacement stable cell lines using 47snoMEN. (a) Images
of protein replacement stable cell lines. Expression of FP proteins was confirmed by fluorescence imaging.
Bar is 10 μm. (b) Expression levels of endogenous SMN1 and GFP-SMN1 proteins were measured by
western blot analysis. An equivalent amount of total cell extract from U2OS and U2OSGFP–SMN1-47PR
stable cells was loaded for each lane and the proteins separated by SDS PAGE, electroblotted and probed
both with a monoclonal anti-SMN1 antibody and with an anti-tubulin antibody as a loading control. (c)
Gene-expression profiles were compared between U2OS and U2OSGFP–SMN1-47PR cells by quantitative
mass spectrometry analysis. Comparison of protein expression levels detected by mass spectrometry for
U2OS and U2OSGFP–SMN1-47PR cells. Each SILAC experiment was independently repeated three times.
Correlation between protein ratios of SILAC experiments visualised on a 2D logarithmic graph for all
detected proteins, identified as previously described [44, 45]. On the x and y axis, log2 (H/L ratio)
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HBII-180C, can be manipulated to create an internal region (M box), that, when complemen-
tary to either mRNA or pre-mRNA sequences, can result in reduced expression (i.e. knock-
down), of both the targeted mRNA and cognate protein [7]. We have shown that snoMEN
RNAs, based on engineered versions of the HBII-180C snoRNA backbone, can be expressed
from either plasmid, or lentiviral vectors and can be used to knock-down targeted microRNAs,
as well as protein coding transcripts [8]. Furthermore, we have shown that snoMEN vectors
can be used to establish stable human cell lines that simultaneously ‘knock-down’ the levels of
a targeted, endogenous protein and ‘knock-in’ expression of either a tagged, or mutant form of
the same protein, using a single vector transcript [9]. Here we have aimed to improve the over-
all efficiency of the snoMEN vector system by characterising alternative snoRNA backbones
suitable for use in targeted gene knock-down and protein replacement studies. Analysis of both
human box C/D and box H/ACA snoRNAs led us to identify the U47 box C/D snoRNA as an
effective backbone for creating snoMEN vectors. We show that the M box region of U47 sno-
MEN can be modified to target knock-down of either FP-tagged fusion proteins, or endoge-
nous cell proteins. We characterise new snoMEN vectors based on multiplexed U47 snoMEN
that provide more efficient knock-down and protein replacement than the previous vectors
based on the use of snoRNA HBII-180C. Thanks to the improved efficiency of the new vectors,
we have now been able to establish stable human cell lines that knock-in GFP-tagged HIF-1α,
which had not been possible using alternative technologies.
Previous studies on nucleolar snoRNAs have extensively characterised their essential role in
catalysing the site specific, post-transcriptional modification of rRNA and other non-coding
RNAs, including tRNAs and snRNAs. In the case of box C/D snoRNAs, which catalyse 2’-O-
ribose methylation by the conserved snoRNP protein fibrillarin, they have a guide region
located immediately 5’ to either the box D, or D’ regions, that is complementary to the RNA
target site for methylation [4, 5] (For example see Fig 1A Green lines). Also called an antisense
box, the guide sequence base pairs with the target, forming an RNA:RNA duplex. The nucleo-
tide targeted for 2’-O-ribose methylation is usually base paired with the fifth residue upstream
from either the box D, or D’ [2, 19] (see Fig 1A). We have demonstrated that these methylation
guide sequences in snoRNAs are not required for target gene knock-down by snoMEN vectors
[7]. In the case of box H/ACA snoRNAs, which catalyse psuedouridine formation by the con-
served snoRNP protein dyskerin, the hairpins contain bulges, or recognition loops, that form
complex pseudo-knots with the target RNA, where the target uridine is the first unpaired base
[2, 3] (see Fig 1A). The position of the substrate uridine always resides 14–16 nucleotides
upstream of either the H box, or of the ACA box. Compared with the snoRNA guide sequences
targeting pseudouridylation, the M box is located at a single stranded region and is not pre-
dicted to form a recognition loop. Taken together, the current evidence suggests that the mech-
anism of targeted gene knock-down by snoMEN is independent of the guide sequences used by
box C/D and box H/ACA snoRNAs to target 2’-O-ribose methylation and pseudouridylation,
respectively.
We have reported that certain mammalian miRNA precursors appear closely related to
snoRNAs, with a subset of miRNA precursors and snoRNAs showing similarities in their pri-
mary and secondary structures (see Fig 1). Indeed, we have also identified known miRNAs
that are encoded within snoRNA-like molecules [20–23] (Fig 1A and Fig B in S1 File). Fur-
thermore, other groups have investigated known snoRNAs that are further processed into
miRNA-like fragments [24–27], supporting a fundamental relationship between snoRNAs and
correlates with the enrichment in U2OS cells and U2OSGFP–SMN1-47PR cells for experiment 1 and
experiment 2, respectively. Graph shows a distribution pattern of plot numbers. SILAC ratio values of
labelled proteins are listed in S2 Data.
doi:10.1371/journal.pone.0154759.g010
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Fig 11. Protein replacement of endogenous HIF-1α protein using 47snoMEN. (a) Structures for the targeted endogenous
HIF-1α protein replacement plasmid using U47snoMEN. (b) Schematic diagram of endogenous HIF complex. (c) U2OS and
U2OSGFP–HIF-1α stable cell lines were exposed to hypoxia prior to lysis and analysed byWestern blot for HIF-1α levels. (d)
U2OSGFP–HIF-1α stable cell lines were transfected with mCherry and treated with DFX for 24 hours. Cells were analysed by
imaging for the levels of HIF-1α (e) Schematic diagram of external HIF-1α protein.
doi:10.1371/journal.pone.0154759.g011
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Fig 12. Protein replacement of endogenous HIF-1α protein by transient transfection. (a) Localisation analysis of endogenous HIF-1α
(no transfection) and mCherry–HIF-1α protein (pmCherry–HIF1α-U47snoMEN-PR) in U2OS cells transiently transfected with the
U47snoMEN-PR plasmid. HIF-1αwas stabilised by DMOG/DFX treatments. While DFX is an iron chelator, DMOG, is a 2-oxoglurate
analogue that blocks enzymes that require this as co-factor, making DMOG slightly more specific. The difference in efficiency in stabilizing
HIF-1α reflects the concentrations of each inhibitor used. Images show localisation patterns of DNA (DAPI, Blue) and endogenous HIF-1α /
mCherry–HIF-1α proteins (Red), respectively. A plasmid vector coding for mCherry alone was also transiently transfected as a negative
control. Scale bar is 10 μm. (b) Expression levels of endogenous HIF-1α and mCherry–HIF-1α were measured by western blot analysis. A
plasmid vector coding for mCherry alone was also transiently transfected as a negative control. The actin signal was used as a loading
control.
doi:10.1371/journal.pone.0154759.g012
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Fig 13. Establishment of a human protein replacement stable cell line using 47snoMEN. (a) Images of protein
replacement stable cell lines (U2OSGFP–HIF-1α-47PR). Expression of FP proteins was confirmed by fluorescence imaging
with DFX treatment. Bar is 10 μm. (b) U2OS and U2OSGFP–HIF-1α-47PR cells were exposed to 1%O2 for the indicated
periods of time prior to lysis. Cell extracts were analysed by western blot using the indicated antibodies. (c) U2OS cells
were transfected with 1 μg of control and HIF-1α -47snoMEN vectors for 48 hours prior to lysis. DFX was added for the
last 24 hours. Cell extracts were analysed by western blot using the indicated antibodies. (d) 3D culture analysis.
HeLaGFP–HIF-1α-47PR cells were cultured in lipidure coated plates to induce spheroid formation. HIF-1α is visible in the core
of the spheroid revealing hypoxia. Bar is 10 μm.
doi:10.1371/journal.pone.0154759.g013
Development and Analysis of a Novel snoMEN Vector
PLOS ONE | DOI:10.1371/journal.pone.0154759 April 29, 2016 21 / 28
miRNAs, which we speculate may be of relevance to the evolutionary origin of some types of
miRNAs. These observations raise the possibility that snoMEN are actually miRNA precursors,
which predicts that the mechanism of knock-down by snoMEN involves the previously charac-
terised miRNA biogenesis pathway. Our previous analyses have indicated that snoMEN-medi-
ated knock-down occurs via a mechanism that may involve the Ago2 and/or Upf1 proteins,
but is independent of Ago1 [9]. In addition, we observe that snoMEN RNAs share characteris-
tic features seen for endogenous snoRNAs, including steady state accumulation in nucleoli,
inactivation by mutations in snoRNA core motifs and binding with conserved snoRNP pro-
teins. This suggests that targeted gene knock-down by snoMEN RNAs may involve a mechan-
sim distinct from the canonical miRNA/shRNA/siRNA maturation pathways, even if some
common components may be involved.
In this study we have identified the U47 snoRNA as a superior snoMEN vector backbone.
Data from FP reporter assays showed that the knock-down efficiency of box C/D type U47sno-
MEN and U77snoMEN was higher than obtained with the box H/ACA type ACA16snoMEN
and miR-566snoMEN, for both mRNA and protein levels (Figs 4 and 5). As the majority of
box H/ACA snoRNAs are longer than box C/D snoRNAs and also form more complex second-
ary and tertiary structures (For example see Fig 1A), it is possible that the stability of shorter
snoRNAs, i.e. box C/D type snoMEN, are more stable than box H/ACA type snoMEN. Based
upon its short size and knock-down efficiency, we concentrated here on developing new sno-
MEN vectors based on the U47 snoRNA backbone.
We previously demonstrated the establishment of human protein replacement stable cell
lines using the original HBII-180C snoMEN vectors [9] (Fig 8B). However, the efficiency of
gene knock-in obtained was relatively low, e.g. FP-tagged versions of proteins replaced ~30%
of the corresponding endogenous protein level (Fig 9). To improve the knock-in efficiency, we
have characterised here vectors using the new U47 snoRNA backbone and also have modified
the vector design to improve exogenous protein expression by locating the cDNA coding
sequence downstream (3’) of the multiplex snoMEN sequences in the knock-in transcript. We
observe that this version of the snoMEN vector resulted in increased (~5 fold higher) expres-
sion of exogenous, knock-in FP-tagged proteins (Fig 9). This may largely result from avoiding
activation of the NMD pathway as a result of locating introns in the transcript downstream of
the stop codon in the cDNA sequence [28–30] (Fig 8A and 8C). In combination with the
improved knock-down efficiency of the targeted endogenous protein resulting from the new
U47 snoRNA backbone, the higher exogenous protein expression from the vector thus pro-
vides a substantial improvement in knock-in efficiency.
Using the improved vector design allowed us to establish new human stable cell lines,
including cells with knock-in of GFP–HIF-1α. Previous work has shown that it is very chal-
lenging to establish stable cell lines expressing knock-in of GFP–HIF-1α using alternative tech-
nological approaches (our unpublished observations). Characterising these protein
replacement stable cell lines using a combination of assays, including fluorescence microscopy
and quantitative mass spectrometry, showed that the 47snoMEN-PR vectors generated effi-
cient knock-in of targeted proteins, with little or no reduction in either cell growth, or viability
and with minimal off-target effects on the expression levels of non-targeted proteins, as judged
by quantitative proteomics analysis. We conclude, therefore, that the 47snoMEN vectors
expand the repertoire of technologies available for manipulating gene expression in mamma-
lian cells and can provide new opportunities for overcoming current limitations in gene expres-
sion studies, as exemplified here for GFP–HIF-1α. We foresee further development of
47snoMEN vectors to expand their utility and applications, e.g. incorporating inducible pro-
moters and delivery using virus-based vectors. With the demonstrated improvements in
knock-in efficiency, we anticipate future applications for 47snoMEN vectors in basic gene
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expression research, in drug screening and target validation studies and possibly also for gene
therapy.
Methods
Secondary structure analysis
All RNA secondary structures were predicted by RNAstructure 4.6 and annotated using Rna-
Viz 2.0.
Cell culture
HeLa and U2OS cells were provided from EMBL and ATCC, respectively. HeLa and U2OS
cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS).
Plasmid construction and transfections
The sequence spanning exon 2 to exon 3 of the C19orf48 gene and the sequence spanning exon
5 to exon 6 of the TBRG4 (transforming growth factor beta regulator 4) gene were inserted 3’
of the CMV promoter in the pcDNA3.1 mammalian expression plasmid (Invitrogen), creating
U47/U77 box C/D type snoMEN and ACA16/miR-566 box H/ACA type snoMEN expression
vectors. SnoMEN and mutant snoMEN derivatives of each snoRNA were established from the
respective wild type snoRNA expression mini gene constructs by site directed mutagenesis.
The plasmids were transfected into either HeLa, or U2OS cells, using “effectine” transfection
regent (QIAGEN).
Fluorescent in situ hybridization (FISH)
FISH procedure was performed as previously described [http://www.singerlab.org/protocols].
HeLa cells were transfected with a plasmid vector containing the snoMEN mini gene expressed
from the CMV promoter. The cells were fixed with 4% paraformaldehyde after pre-permeabili-
zation with 1% tritonX-100. After 70% ethanol treatment, a Cy-3 labeled snoMEN specific oli-
gonucleotide probe (CM1: 5’-GCAGCACGACUUCUUCAAGUC-3’, CM2: 5’-GCAGAAGAA
CGGCAUCAAGGU-3’ CM3: 5’-CAGCCACAACGUCUAUAUCAU-3’) was hybridized with
Fluorescein labelled U3 specific oligonucleotide probe (5’-ACCACUCAGACCGCGUUCUC
UCCC-3’) as a nucleolar marker, using standard procedures. The fluorescence signal was
imaged using a Deltavision Spectris fluorescence microscope (Applied Precision). The specific
probes for each of the snoRNAs (U47: 5’-UGGAACGGUUUUACAGUGAUAUC-3’, U77:
5’-ACAUCUCUUCAUGAUUAAAUCUGCUG-3’, ACA16: 5’-ACCGUCAAGGAAAAC
UGUCACUCUGGGC-3’, miR-566: 5’-GUUGGGAUCACAGGCGCCC-3’) were also labelled
with Cy-3.
Microscopy imaging and antibodies
All cell images were recorded using the DeltaVision Spectris fluorescence microscope (Applied
Precision). Live cell images were prepared as previously described (http://www.lamondlab.
com/f7protocols.htm). Cells were imaged using a 60x (NA 1.4) Plan Apochromat objective.
Twelve optical sections separated by 0.5 μmwere recorded for each field and each exposure
(SoftWoRx image processing software, Applied Precision). Primary antibodies against SMN1
(BD Transduction Laboratories), fibrillarin (72b9) [31], Dyskerin (Sigma-Aldrich) and coilin
(5P10) [32] were used for immunostaining. Primary antibodies against HIF-1α (610958, BD
Biosciences), HIF-1β (3718, Cell Signaling), CAIX (NB100-417, Novus Biologicals), PHD2
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(Bethyl A300-322A), BNIP3 (ab10433, Abcam), PHD3 (A300-327A, Bethyl labs) and Actin
(3700, Cell Signaling) were used for immuno blotting analysis.
Immunoprecipitation and RT-PCR
Immunoprecipitations were prepared as previously described [20, 33–36]. Nuclear lysates were
prepared from HeLaYFP-Fibrillarin [33], HeLaGFP-Dyskerin [20] and HeLaGFP [20, 33] stable cell
lines. Purified nuclei were resuspended in RIPA buffer to solubilize proteins. Fluorescent pro-
teins were immunoprecipitated using an anti-GFP monoclonal antibody (GFP–TRAP_A,
Chromotek), as previously described [20, 33]. Samples were divided in two and for Input sam-
ples RNA was isolated from one half of each nuclear lysate. RNA was isolated by the TRIzol
method with DNase I treatment, according to manufacturer’s instruction (Invitrogen).
RT-PCR was performed to detect immunoprecipitated RNAs. Reverse transcription and PCR
were performed with the following gene-specific primers,
U3: 5’-AGAGGTAGCGTTTTCTCCTGAGCG-3’ and 5’-ACCACTCAGACCGCGTTCTC-3’,
E2: 5’-GGAGTTGAGGCTACTGACTGGC-3’ and 5’-CCACTCATTGGGCCAGAGACCC-3’,
U47snoMEN: 5’-TAATGATTCTGCCAAATGAATCACC-3’ and 5’-ACCTCAGAATCAAAATGGAA
CGGC-3’,
U77snoMEN: 5’- AGATACTATGATGGTCACCTTGATGC-3’ and 5’-
AGATACTATGATGGTTGCATAGTTCAG-3’,
ACA16snoMEN: 5’-TGCTTCCGCATAGCTGCTGTGG-3’ and 5’-
CAAGCAGAAGCAGTTACAACAAACAG-3’
miR-566snoMEN: 5’-ACCTTGATGCCGTTCTTCTGC-3’ and 5’-GGTTCAAGCGATTCTGCTG
CCC-3’
HBII-180C snoMEN: 5’-ACCTTGATGCCGTTCTTCTGC-3’ and 5’-CTCAGACCCCCAGGTGTC
AA-3’,
using the one-step RT-PCR kit (QIAGEN). To decide linearity of cycles, we carried out real
time PCR using the QuantiFast SYBR Green one-step qRT-PCR Kit (QIAGEN) and Light
Cycler 480II (Roche). The same amount of RNA for input and immunoprecipitated RNA (IP)
was used as templates for RT-PCR reactions. Each experiment was repeated three times
independently.
Quantitative RT-PCR (qRT-PCR)
The qRT-PCR was performed to measure GFP-SMN1 expression level after snoMEN plasmid
transfections. Equal amounts of total RNA from HeLa cells, extracted following snoMEN
transfections, were used for qRT-PCR reactions. The GFP-SMN1 mRNA expression ratio
between control and snoMEN transfection measured from four independent experiments.
GFP specific primers (5’-GACCACTACCAGCAGAACACCC-3’ and 5’-TGTGATCGCGC
TTCTCGTTGGG-3’) U3 mRNA specific primers (5’-AGAGGTAGCGTTTTCTCCTGAGC
G-3’ and 5’-ACCACTCAGACCGCGTTCTC-3’), as a loading control, were used for
amplification.
Quantification analysis of blotting images
All signal intensities of Western blotting images were analysed using imaging software (Image
Gauge v4.21; Fujifilm) with the default manufacturer’s procedure. Briefly, the same size of
pixel area was selected and signal intensity calculated by subtraction of the background signal.
Each signal was normalised with reference to standard control signals, e.g. tubulin, and a signal
to control ratio was calculated.
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Proliferation/cytotoxicity assay
Proliferation/cytotoxicity assays were performed using alamarBlue (AbD Serotec) as described
by the supplier. Fluorescence was measured using a CLARIOstar plate reader (BMG
LABTECH).
Stable isotope-labelling of cellular proteins and mass spectrometry
sample preparations
SILAC experiments were performed as previously described [34–40]. Cells were grown for at least
six cell divisions in L-arginine-, or L-arginine 13C6
15N4-labelling media before analysis. Cells were
resuspended in 8% Urea—0.1M TEAB buffer to solubilize proteins. Lysates from each cell were
mixed in a 1:1 ratio based on total protein concentration and sonicated to fragment genomic
DNA. Proteins were reduced with TCEP (25 mM in denaturing urea buffer) and alkylated with
iodoacetamide. Lysates were diluted with digest buffer (100 mM Tris pH 8.0 + 1 mMCaCl2) to
reach 4 M urea, and then digested with 1:50 Lys-C (Wako Chemicals, Japan). The digest was
diluted with digest buffer to reach 0.8 M urea and digested with trypsin (Promega; 1:50). The
digests were then desalted using SepPak-C18 SPE cartridges, dried and resuspended in 80% Ace-
tonitrile, 0.1% TFA. Peptides were separated using a Dionex Ultimate 3000 HPLC system
equipped with a HILIC (hydrophilic interaction liquid chromatography) column, using a similar
protocol to the hSAXmethod described previously [41]. The peptide fractions were desalted using
SepPak-C18 SPE plates and then resuspended in 5% formic acid for LC-MS/MS analysis.
Mass spectrometry and data analysis
For Trypsin+Lys-C double digests, peptide chromatography was performed using a Dionex
RSLCnano HPLC. Peptides were injected directly onto a 75 μm × 50 cm PepMap-C18 column
using the following mobile phases: 2% acetonitrile +0.1% formic acid (Solvent A) and 80% ace-
tonitrile +0.1% formic acid (Solvent B). The linear gradient began with 5% A to 35% B over
220 min with a constant flow rate of 200 nl/min. The peptide eluent flowed into a nanoelectros-
pray emitter at the front end of a Q-Exactive (quadrupole Orbitrap) mass spectrometer
(Thermo Fisher). A typical ‘Top10’ acquisition method was used and an in-house developed
software (Peptracker [42]) was used to evaluate peptide identifications and abundance ratios.
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consor-
tium via the PRIDE [43] partner repository with the dataset identifier PXD003622.
Drug treatments
MG132 was obtained fromMerck Millipore and used at 20μM final concentration for 3 hours,
Desferroxamine (DFX) was obtained from Sigma and used at the final concentration of 200μM
for 24 hours, Dimethyloxalylglycine (DMOG) was obtained fromMerck Millipore and used at
a final concentration of 1mM for 24 hours.
Hypoxia treatment and 3D culture analysis
Cells were incubated at 1% O2 in an in vivo 300 hypoxia workstation (Ruskin, UK). Cells were
lysed for protein extracts in the workstation to avoid reoxygenation. For 3-D culture, Lipidure
plates (NOF America Corporation #51011610) were used for spheroid formation due to their
improved reproducibility over conventional methods and the formation of a single, central
spheroid. Lipidure plates are pre-coated with phosphorylcholine to supress cell adhesion. 200μl
of 5x104 live cells per mL were seeded per well and spheroids allowed to form overnight.
Growth of formed spheroids was documented by light microscopy
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